Pfizer vs. AbbVie: Higher Yield and Cheaper Valuation Give One the Clear Edge
Pfizer vs. AbbVie: Higher Yield and Cheaper Valuation Give One the Clear Edge Yahoo Finance
Covered in this story
What has happened since
- AbbVie is up 1.3% since this was published, 8 days ago.
- Pfizer is down 1.7% since this was published, 8 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on AbbVie
- RBC Capital Markets: at $289 · target $330 by Nov 2027 · Outperform via Investing.com
- Wells Fargo: at $289 · target $340 by Nov 2027 · Overweight via Investing.com
- UBS: at $276 · target $275 by Oct 2027 · Neutral via GuruFocus
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 34 stories mentioning AbbVie, the earliest published 6 Jan 2013.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.